Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Faber

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Cancer Discovery|December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsAnthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Cancer Cell|December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsRyan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Cancer Research Communications|December 12, 2022
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1Richard Kurupi, Konstantinos V Floros, Sheeba Jacob, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2018
Coamplification of <i>miR-4728</i> protects <i>HER2</i>-amplified breast cancers from targeted therapyKonstantinos V Floros, Timothy L Lochmann, Bin Hu, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
Nature Communications|October 8, 2025
Exercise facilitates post-stroke recovery through mitigation of neuronal hyperexcitability via interleukin-10 signalingA Schmidt-Pogoda, T Ruck, J K Strecker, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIMKyung-A Song, Matthew J Niederst, Timothy L Lochmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Cancer Discovery|December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsAnthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Cancer Cell|December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsRyan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Cancer Research Communications|December 12, 2022
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1Richard Kurupi, Konstantinos V Floros, Sheeba Jacob, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2018
Coamplification of <i>miR-4728</i> protects <i>HER2</i>-amplified breast cancers from targeted therapyKonstantinos V Floros, Timothy L Lochmann, Bin Hu, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
Nature Communications|October 8, 2025
Exercise facilitates post-stroke recovery through mitigation of neuronal hyperexcitability via interleukin-10 signalingA Schmidt-Pogoda, T Ruck, J K Strecker, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIMKyung-A Song, Matthew J Niederst, Timothy L Lochmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Pageof 20